Cargando…

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia

BACKGROUND: Replacement therapy is the most common treatment for reduction of bleeding and control of episodic bleeding in individuals with hemophilia. Despite the proven effectiveness of factor replacement therapy, repeated intravenous administration is a heavy burden to individuals with hemophilia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwak, Heechun, Lee, Sumin, Jo, Seunghyun, Kwon, Young Eun, Kang, Hyunju, Choi, Gahee, Jung, Myung Eun, Kwak, Mi‐Jeong, Kim, Seonghoon, Oh, Byung‐Ha, Kim, Dong‐Sik, Hwang, Sung Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles ‐ Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695563/ https://www.ncbi.nlm.nih.gov/pubmed/33313469 http://dx.doi.org/10.1002/rth2.12438

Ejemplares similares

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
por: Schöchl, Herbert, et al.
Publicado: (2017)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Traumatic vessel injuries initiating hemostasis generate high shear conditions
por: Yakusheva, Alexandra A., et al.
Publicado: (2022)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Cryo-EM structure of coagulation factor V short
por: Mohammed, Bassem M., et al.
Publicado: (2023)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)

Lower-leg injury and knee arthroscopy have distinct effects on coagulation
por: Touw, Carolina E., et al.
Publicado: (2022)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia
por: Hisada, Yohei, et al.
Publicado: (2023)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A
por: Hiramoto, Takafumi, et al.
Publicado: (2023)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Role of ribosomal RNA released from red cells in blood coagulation in zebrafish and humans
por: Alharbi, Abdulmajeed, et al.
Publicado: (2021)

Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19
por: Henderson, Michael W., et al.
Publicado: (2022)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation
por: Wan, Jun, et al.
Publicado: (2022)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Soluble protein C receptor: why?
por: Geiger, Margarethe
Publicado: (2008)

Screening platelet function in blood donors
por: Pedini, Pascal, et al.
Publicado: (2022)

Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials
por: Khayat, Claudia Djambas, et al.
Publicado: (2022)

Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
por: Dover, Saunya, et al.
Publicado: (2020)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Patient selection for hemophilia gene therapy: Real‐life data from a single center
por: Krumb, Evelien, et al.
Publicado: (2021)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7qss7g25f4j47movr334dv5ljg